greeksoup/ stock research
Stock research / United States / AMPH / FY2012

Amphastar Pharmaceuticals (AMPH) FY2012 results: revenue $204 million

Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $204 million for fiscal 2012, the year ended 31 December 2012. Net income was $18 million, and diluted earnings per share $0.46. The figures are the company's own, from the 10-K it filed with the SEC on 26 March 2015.

Revenue
$204 million
FY2012FY2012
Operating margin
12.4%
FY2012FY2012
Net income
$18 million
FY2012FY2012
Diluted EPS
$0.46
FY2012FY2012

this yearthe year beforeHover a bar for its figure.

The year in brief

Income statement (profit and loss)

$ millionFY2012Last 8 years
Revenue204
Cost of revenue114
Gross profit90.3
Gross margin44.2%
Research and development31.2
Operating income25.4
Operating margin12.4%
Interest expense0.8
Pre-tax income25.9
Income tax7.8
Effective tax rate30.1%
Net income18.1
Net margin8.9%
Diluted EPS$0.46
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionFY2012Last 8 years
Operating cash flow-1.6
Capital expenditure23.1
Free cash flow-24.8
Free cash flow margin-12.1%
Depreciation and amortisation11.5
Share-based compensation6.7
Buybacks0.8
Diluted shares, weighted39m

Balance sheet

$ millionFY2012Last 8 years
Shareholders' equity233
Goodwill0.3
Cash and equivalents50.2

10-K for the year ended 31 December 2012, filed 26 March 2015: the filing.